News

Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...
The American Journal of Managed Care19h
Breaking Ground in Breast Cancer: A New Standard in TNBC, a New Way to Target ESR1
Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...
STAT19h
Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows
The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...